ETON Eton Pharmaceuticals, Inc.

NASDAQ
$60.85

Eton Pharmaceuticals, Inc. (ETON) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

Insider signal Bearish Selling ran elevated versus ETON's own trailing one-year pace, with 0% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 0 buyers in the last 90 days 4 sellers in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
4
15 transactions
Purchases
$0
0 shares
Sales
$13.3M
213,221 shares
Net activity
-$13.3M
purchases less sales

How much of that selling was preplanned? 0% planned / 100% discretionary

10b5-1 plan sales $0 0 transactions · 0 shares
Discretionary sales $13.3M 15 transactions · 213,221 shares

Largest single sale: $2.3M.

Where they traded

Buy Sell Dot area is proportional to transaction value.

No open-market insider purchase on record.

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
CASAMENTO CHARLES J 5 fills Director Sell 80,555 $66.35 $5.3M 74,175 −52.1% of holding
Erdogan-Trinkaus Ipek 2 fills Chief Commercial Officer Sell 3,500 $67.41 $235.9K 5,241 −40% of holding
Krempa David Chief Business Officer Sell 4,166 $55.07 $229.4K 43,381 −8.8% of holding
MAIER PAUL V 6 fills Director Sell 100,000 $59.07 $5.9M 73,358 −57.7% of holding
Krempa David Chief Business Officer Sell 25,000 $65.07 $1.6M 37,025 −40.3% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.